Daily Round Up 4/12/16: Conn's, Verint Systems, Impac Mortgage, Atyr Pharma

by: InsiderInsights


Tables of the top insider purchases and sales filed with the SEC on 4/12/16, based on dollar value.

Dollar values often do not equate with significance when it comes to insider trades.

Proprietary Insider Company Ratings are relayed to clarify significance.

Dollar value is only one metric to assess the significance of an insider transaction, but when high dollar value intersects with significance it spotlights a stock investors should take the time to consider. InsiderInsights Daily Round Up articles are intended as initial research tools, so investors can separate real insider investment intelligence from time-wasting noise.

Click the Company Name links in the tables below to analyze a company's or insider's full insider history.

Educational note from InsiderInsights:

Insider filing volumes are at a seasonal low point due to companies closing trading windows to their insiders until quarterly earnings are released. As a result, the dollar values of trades featured in our Daily round Up articles (particularly the purchases) will likely be lower than usual until early May.

On Today's Tables:

Insider trades were rated Significant at:

  • Verint Systems (NASDAQ:VRNT);
  • Atyr Pharma (NASDAQ:LIFE);
  • Impac Mortgage (NYSEMKT:IMH);
  • Virtus Total Return Fund (DCA), and;
  • Conns (NASDAQ:CONN).

Insider trades were rated Nearly Significant at:

  • Citius Pharm (NASDAQ:CTXR), and;
  • Legg Mason (NYSE:LM).

Insider trades were considered Insignificant at:

  • S & W Seed (NASDAQ:SANW);
  • Barnes & Noble Education (NYSE:BNED);
  • Supernus Pharm (NASDAQ:SUPN);
  • Universal Display (NASDAQ:OLED);
  • Monolithic Power (NASDAQ:MPWR);
  • Alphabet (NASDAQ:GOOG);
  • Acuity Brands (NYSE:AYI);
  • Adobe Systems (NASDAQ:ADBE), and;
  • American Capital (NASDAQ:ACAS).

There is a Conflicted Insider Signal (both purchases & sales) at:

  • Sears (NASDAQ:SHLD), and;
  • Criteo S A (NASDAQ:CRTO).

There is an IPO or Known Corporate Action at:

  • Aeglea Biotherapeutics (NASDAQ:AGLE).

It's difficult to argue significance for most transactions made during IPOs, or when insiders make trades during a known corporate action.

Insider Purchases

#: Filer Name Insider Titles Company Name Ticker Trans
Dollar Value
1 Novartis Bioventures BO Aeglea Biotherapeutics AGLE JB* $3,000,000
2 Mazur Leonard L DIR Citius Pharm CTXR JB* $3,000,000
3 Stephens Warren A BO Conns CONN B $2,684,950
4 Lampert Edward S CEO,DIR,BO Sears SHLD B $821,267
5 Bulldog Investors BO Virtus Total Return Fund DCA B $221,293
6 Schimmel Paul DIR Atyr Pharma LIFE B $116,535
7 Quinn Anthony DIR Aeglea Biotherapeutics AGLE B $100,000
8 Abrams Capital BO Barnes & Noble Education BNED B $83,742
9 Wynnefld SmCap Val BO S & W Seed SANW B $77,912
10 Pickup Todd M BO Impac Mortgage IMH B $71,982

Source: | Key to Insider Title and Trans Type Codes :
B =Open-market Buy; AB=10b5-1 (automatic) Buy; JB*=Buy indicated as being open-market, but not confirmed by trading price range and volume for the session.

Insider Sales

#: Filer Name Insider Titles Company Name Ticker Trans
Dollar Value
1 Trian Fund Mgt BO Legg Mason LM JS* $673,673,792
2 Drummond David C VP Alphabet GOOG AS $3,741,075
3 Xiao Deming PR,OO Monolithic Power MPWR AS $2,063,261
4 Bodner Dan CEO,DIR Verint Systems VRNT S $1,384,365
5 Brown Julia J CTO Universal Display OLED AS $1,375,000
6 Erickson John R CFO,PR American Capital ACAS AS $855,368
7 Black Mark A VP Acuity Brands AYI S $664,573
8 Niccoli Romain CTO Criteo S A CRTO AS $594,223
9 Bhatt Padmanabh P VP Supernus Pharm SUPN AS $507,228
10 Warnock John E CB,DIR Adobe Systems ADBE S $466,458 | Key to Insider Title and Trans Type Codes :
S =Open-market Sale; AS=10b5-1 (automatic) Sale; JS*=Sale indicated as being open-market, but not confirmed by trading price range and volume for the session.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.